Janus Henderson Group plc Acquires 9.9% Stake in Minerva Neurosciences, Inc. (NERV)

On May 15, 2026, Janus Henderson Group plc filed a Schedule 13G reporting a new significant stake in Minerva Neurosciences, Inc. (NERV). As of the event date of March 31, 2026, the filer beneficially owns 4,307,759 shares of common stock, representing a 9.9% ownership stake in the company. This position includes 9,000 pre-funded series A Warrants and 4,500 series A Warrants. Janus Henderson Group plc acts as the ultimate parent company for various SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited, which exercise investment and voting discretion over the shares on behalf of managed portfolios. Specifically, the Janus Henderson Biotech Innovation Master Fund Ltd. was identified as having the right to receive dividends or sale proceeds from more than 5% of the common stock. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.